

# Connie P Duong

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6734656/connie-p-duong-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24  
papers

5,715  
citations

17  
h-index

26  
g-index

26  
ext. papers

7,696  
ext. citations

15.7  
avg, IF

4.63  
L-index

#	Paper	IF	Citations
24	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , <b>2021</b> , 27, 1432-1441	50.5	57
23	Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis.. <i>Cancer Discovery</i> , <b>2021</b> ,	24.4	4
22	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. <i>European Urology</i> , <b>2020</b> , 78, 195-206	10.2	67
21	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , <b>2020</b> , 26, 919-931	50.5	55
20	Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. <i>Science</i> , <b>2020</b> , 369, 936-942	33.3	74
19	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. <i>Cell Research</i> , <b>2019</b> , 29, 846-861	24.7	91
18	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , <b>2018</b> , 359, 91-97	33.3	2203
17	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2480	8.4	35
16	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Onc Immunology</i> , <b>2017</b> , 6, e1299303	7.2	14
15	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , <b>2016</b> , 45, 931-943	32.3	376
14	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , <b>2015</b> , 350, 1079-84	33.3	1689
13	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. <i>Molecular Immunology</i> , <b>2015</b> , 67, 46-57	4.3	81
12	Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. <i>Molecular Therapy</i> , <b>2014</b> , 22, 18-27	11.7	83
11	Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. <i>Leukemia Research</i> , <b>2014</b> , 38, 948-54	2.7	12
10	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. <i>Onc Immunology</i> , <b>2014</b> , 3, e963395	7.2	7
9	Foxp3 expression in macrophages associated with RENCA tumors in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e108670	3.7	17
8	Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. <i>Immunotherapy</i> , <b>2013</b> , 5, 577-90	3.8	5

7	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5636-46	12.9	485
6	Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. <i>PLoS ONE</i> , <b>2013</b> , 8, e63037	3.7	34
5	Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 1651-60	10.1	85
4	Autoimmunity associated with immunotherapy of cancer. <i>Blood</i> , <b>2011</b> , 118, 499-509	2.2	128
3	Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. <i>Immunotherapy</i> , <b>2011</b> , 3, 33-48	3.8	39
2	Tumor ablation by gene-modified T cells in the absence of autoimmunity. <i>Cancer Research</i> , <b>2010</b> , 70, 9591-8	10.1	46
1	Enhancing adoptive immunotherapy of cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 531-45	5.4	12